Get the Stockscreener App
35.87
2.07%
-0.76
Vaxcyte Inc stock is traded at $35.87, with a volume of 1.14M.
It is down -2.07% in the last 24 hours and up +10.10% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$36.63
Open:
$36.59
24h Volume:
1.14M
Relative Volume:
0.65
Market Cap:
$4.63B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-7.7978
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+0.65%
1M Performance:
+10.10%
6M Performance:
-61.07%
1Y Performance:
-57.32%
1-Day Range:
$35.77
$36.74
1-Week Range:
$35.25
$37.00
52-Week Range:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
35.87 | 4.73B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Should I hold or sell Vaxcyte Inc. stock in 2025Best Dividend Insights For Fast Growth - jammulinksnews.com
What institutional investors are buying Vaxcyte Inc. stockChart Pattern Ideas For Fast Growth - jammulinksnews.com
What is the risk reward ratio of investing in Vaxcyte Inc. stockInvest smarter with daily stock recommendations - jammulinksnews.com
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsSmart Portfolio Ideas For Fast Growth - jammulinksnews.com
Is Vaxcyte Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - jammulinksnews.com
How strong is Vaxcyte Inc. company’s balance sheetPhenomenal investment performance - jammulinksnews.com
Is Vaxcyte Inc. a growth stock or a value stockRemarkably fast returns - jammulinksnews.com
What catalysts could drive Vaxcyte Inc. stock higher in 2025Rapid growth trajectories - jammulinksnews.com
When is Vaxcyte Inc. stock expected to show significant growthGet insider insights into market trends - jammulinksnews.com
Is it the right time to buy Vaxcyte Inc. stockCapitalize on fast-moving trading opportunities - jammulinksnews.com
What analysts say about Vaxcyte Inc. stockExceptional ROI - PrintWeekIndia
What drives Vaxcyte Inc. stock priceHigh-yield trading alerts - Autocar Professional
Vaxcyte Inc. Stock Analysis and ForecastRapid market gains - jammulinksnews.com
Is Vaxcyte Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) - MSN
Nisa Investment Advisors LLC Buys 293 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
Vaxcyte’s High-Stakes Bet On Next-Gen Pneumonia Vaccines - Finimize
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):